Paton, et al. (2002) [19]  non-comparative clinical study22 asymptomatic HIV-1 infected patients  HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.48 weeks  In the 12th week there was a significant reduction of 1.3 log10 in viral load and an increase in CD4+ percentage by mean 4.3%. These values were maintained until the 48th week.  Not reported.  Small sample-size.This is a non-comparative design pilot study which not allow determining the contribution made by HCQalone to the overall decrease in viral load obtained by the combination.